A B S T R A C T Aspirin inhibits platelet frinction by permanently acetylating the cyclooxygenase that forms prostaglandins. We determined the sensitivity of platelets to aspirin in normal subjects by measuring [3H-acetyl]aspirin-susceptible cyclooxygenase in washed platelets obtained at various times after aspirin ingestion. A single 325-mg aspirin dose inactivated 89% of platelet cyclooxygenase. The inhibition persisted for 2 days suggesting that oral aspirin also inactivated megakaryocyte cyclooxygenase. Thereafter, active enzyme returned with a time-course reflecting platelet turnover (life-span 8.2+2 days). Single doses of 20-650 mg aspirin resulted in 34->95% inhibition after 24 h. Daily doses of 20-325 mg aspirin for brief periods produced 61->95% inactivation when measured 24 h after cessation of the drug. Platelet cyclooxygenase is more sensitive to inactivation by aspirin than enzyme in sheep seminial vesicles.
INTRODUCTION
Platelets are involved in the generation and propagation ofthrombi, particularly arterial thrombi (2, 3) . They may also be important in the pathogenesis of atherosclerosis (4) . A number of clinical trials have been initiated attempting to define the usefulness of antiplatelet agents in disease states associated with embolic or thrombotic phenomena (5, 6) . Recent randomized controlled studies utilizing aspirin for prevention of death from a second myocardial infarction suggest that the drug may be effective although the results are not conclusive (7, 8) .
Aspirin ingestion alters platelet fiunction in vivo, as evidenced by a prolonged bleeding timiie (9) , and alters This work was presented in part at the AInInual Meeting of The Association of American Phvsicians, Washington, D. C., the results of some in vitro platelet function tests (10, 11) . These effects are due to the inhibition of prostaglandin biosynthesis by aspirin (12) . Aspirin irreversibly acetylates cyclooxygenase (prostaglandin synthetase), the initial enzyme in the prostaglandin biosynthetic pathway (13, 14) . The aspirin concentration required for enzyme inactivation is the same as that required to inhibit platelet function (14) . In platelets the product of cyclooxygenase, prostaglandin G2 (PGG2),i is converted to thromboxane A2 (15) , which can stimulate the platelet release reaction. (PGG2 can also cause platelet aggregation and release, although it is less potent than thromboxane A2.) Thromboxane A2 is a potent vasoconstrictor; its release into the plasma (16) could mediate the vasospasm accompanying thrombotic episodes. Therefore, by blocking the production of PGG2 and thromboxane A2 in platelets, aspirin may have an antithrombotic effect. In arterial tissues one product of arachidonic acid metabolism is prostaglandin 12 (PGI2, 17) , a compound which is a vasodilator and which inhibits platelet aggregation in vitro. Prostaglandin 12 may serve a protective function physiologically by preventing platelet aggregation and vasoconstriction in undamaged areas of the vascular tree. Aspirin, by blocking the production of potentially protective compounds such as PGI2 in addition to thromboxane A2, could have unfavorable effects. O'Brien (10) has shown that platelet function can be inhibited by oral doses of aspirin as small as 160 mg. We recently have demonstrated that cyclooxygenase in cultured smooth muscle cells from human aorta and in skin fibroblasts is more resistant to inactivation by aspirin than the platelet enzyme (18) . In theory an aspirin dose which inhibits only the platelet enzyme would be the most reasonable one to evaluate for an antithrombotic effect and should be associated with the least side effects.
I Abbreviation used in this paper: PG, prostaglandin (used variously according to the identification of a given prostaglandin, i.e., PGG2 or PGI2). (20) . Platelet numbers were estimated by a "microhematocrit" method (21) . Wrhere nioted below, platelets were isolated from svhole blood by ceentrifugation through a discontinuous gradient of Stractan (22) , washed twice in 0.033 M phosphate buffer, pH 6.5 (20) , and resuspended in 0.015 NI Tris buffer, pH 7.4 (20) (24) . Under the conditions described above, cyclooxygenase is the only protein in the particulate fraction of human platelets that is acetylated by aspiriin (14, 24) .
The precipitate was collected l)y ceintrifiugationi at 15,000 g for 10 nmii and was dissolved in a mixtture containinig 0.01 NI sodium phosphate, pH 7.4; 5% sodiuim dodecyl sulfate; 0.1 NI 2-mercaptoethanol; 8% sUcrose; an1d 0.01% l)romophenyl blue. [3H-acetyl]cyclooxygenase conitenit was theni assayed lb polyacrnlamlide gel electrophoresis as described previously (14) .
A platelet life-spain for each stubject was caleulated from the data presented in Fig. I (14) .
RESULTS
Inactivation of platelet cyclooxygenase by oral aspirin was measured as a reduction in the ability of [3H-acetyl]-aspiriin to acetylate the enzyme in washed platelets in vitro, as described in Methods. 16 subjects were giveni a single 325-mg aspirin dose on day 0. Tritium incorporation into platelet cyclooxygenase was measured in platelets from serial blood samples as shown in Fig. 1 . We noted an initial fall in tritium incorporation to 11% of control values 6 h after aspirin ingestion. No new platelet enzyme appeared in the circulation for _2 days. Thereafter, unacetylated enzyme returned with a time-course consistent with platelet tuirnover. A platelet life-span of 8.2+2 days (mean+SD) was obtained for the 16 subjects. We interpret the "lag" in the return of unacetvlated enzyme to the circulation as evidence that aspirin acetylates cyclooxygenase in the megakaryocyte. Platelet protein recovery per unit blood sample did not vary significantly' (Student's t test, 25) at any time point; therefore, the lack of increment in tritium incorporation at 24 and 48 h implies that platelets entering the circulation during this time did not have more active cyclooxygenase than platelets in the circulation 6 h after aspirin ingestion. Furthermore, an identical pattern of enzyme recovery was seen after a single aspirin dose of 650 mg or a brief course of 325 mg per day (data not shown). Either of these latter doses will result in complete enzyme inactivation (acetylation) 6 h after ingestion.
Groups of subjects were given single aspirin doses of 20, 80, 160, and 650 mg. Unacetylated enzyme was measured at 24 h after ingestion and compared to levels measured immediately' before ingestion (i.e., each sub- ject served as his own control). We found a direct relationship between the degree of enzyme inactivation and the amount of aspirin ingested (Table I) . In vitro, the acetylation of cyclooxygenase by aspirin follows pseudo-first order kinetics; that is, the degree of inactivation is directly proportional to the dose of aspirin and the time of exposure (see below). This relationship does not strictly hold when degree of acetylation is compared to oral aspirin dose, inasmuch as the relationship between ingested aspirin dose and effective plasma aspirin concentration is undoubtedly complex. We also gave groups of subjects daily doses of 20, 80, and 325 mg per day for 6, 5, and 7 days, respectively, and measured acetylation 24 h after the last aspirin ingestion (Fig. 2) . Again a direct relationship of dose to enzyme inhibition was seen. 20 mg aspirin per day isolating an especially sensitive subpopulation of platelets by our procedures, platelets were isolated by density gradient centrifugation in Stractan gradients, a method which yields >90% of platelets from whole blood (22) . Platelet yields from 30 ml whole blood by our usual procedures averaged 3.4 x 109; by using the Stractan method, yields averaged 9.0 x 109. No difference in residual enzyme activity was noted in platelets isolated by the two methods in two subjects after the ingestion of 325 mg aspirin daily for 6 days and 160 mg aspirin daily for 6 days, respectively; in both cases >95% inhibition was seen. In another experiment after a single 325-mg aspirin dose, there were 17% residual enzyme in platelets isolated by the standard method and 10% residual enzyme in platelets isolated using Stractan gradients. Therefore, our methods do not induce sampling errors that could account for the aspirin sensitivity noted above.
To assess further the relative sensitivity of platelets to aspirin, we evaluated cyclooxygenase activity in washed platelets exposed to aspirin in vitro and compared the results to cyclooxygenase in acetone-pentane powders of sheep seminal vesicles. These experiments were performed in the presence of a large excess of aspirin, resulting in pseudo-first order kinetics for the acetylation reaction2. In the presence of 100 AM aspirin, the inactivation of sheep seminal vesicle enzyme proceeded with a t1/2 of 10 min yielding a kapparent of 0.069 min-'. In the presence of 10 ,uM aspirin, platelet enzyme was inactivated with a t1,2 of 3.2 min and a kapparent of 0.217 min-'. We define a potency term as kapparent/(aspirin concentration). The potency of aspirin toward sheep seminal vesicles is therefore 690 min-mM-1; toward intact platelets it is 21,700 min-IM-1.
This represents a 31-fold greater sensitivity of platelets relative to sheep seminal vesicles. The greater sensitivity of platelet enzyme is not due to transport of the drug by platelets because the same differences were observed when aspirin was added to disrupted rather than intact platelets. The same difference was also seeni when fresh seminal vesicle microsonmes were used instead of the acetone-pentane powder. DISCUSSION We have determined the dose of aspirin required to inactivate cyclooxygenase by directly measuring the degree of acetylation of the enzyme. This method is 2 A plot of log [fraction unacetylated enzyme] versus time is linear. The slope of this line equals the apparent rate constant, kapparent, and is determined as In 2 divided bv time to half acetylation. The apparent rate constanit is directly proportional to aspirin concentration (13) . Therefore, the ''potency" term (see below), defined as kapparent divided by aspirini concentration, reflects the rate constant of the reactioni with various tissues. much more sensitive thani in vitro assays of platelet ftunction or assays of products of prostaglandin synthesis such as malonaldehvde, and allows mneasuremeint of low levels of residual activity. Small single doses of aspirin cause prompt inactivation of enzyme; no new enzyme appears in circulating platelets for approximately 2 days indicatinig that megakaryocyte cyclooxygenase is also inactivated. O'Brien (10) initially suiggested that megakaryocytes were altered by aspirini because of a similar lag period in recovery of in vitro platelet aggregation after aspirin. Several other studies of aspirin's effect on platelets are conisistenit with the hvpothesis that megakarvocvte enzy me is inactivated (26) (27) (28) . Alternative theories, suich as anl aspirin-senisitive nonexchangeable pool of nlew platelets in the spleen (29) would also explain a 2-day lag period; however, this seems to us to be a less likely possibility. Assuming a 2-day lag before enzyme recovery, we nmeasured a platelet life-spani of 8.2±2 days. This is consistent with other estimiiates of platelet life-spani obtaiined by radioisotope methods (30) or by N-ethylmaleimide induced mlalonaldehvde formation after aspirini ingestion (31) .
A daily dose of 20 mg aspirin per day will result in >50% enzyme inactivationi. A variety of evidence suggests that other tissues max be less seinsitive to aspirini. Thus, analgesic and antiinflammatory doses of aspirin range from 325 mg to 4 g per day (32). Halushka et al. (33) have shown that large doses (30( mg/kg IV) of aspirin in dogs completely block platelet aggregation and platelet arachidoniic acid metabolism buit have no effect oIn myocardial synthesis of immunoreactive prostaglaildin E-like material. Paternio et al. (34) mleastured prostaglanldinl productionl in humillani synovial tisstue and in intact platelets perfused withiaspirin in vitro. They fouindl that platelets were six-fold mlore seinsitive to aspirini thain synovium, whereas the tissues were equally senisitive to indomiiethacini and fenoprofeni. Collier and Flower (35) acnd Horton et al. (36) have showin decreased, but persisteint, prostaglaindini conitenit in human semen after aspirin doses of up to 7.2 g per day. Prostaglandin E coniteInt in hunman seimien dropped by 58% (35) aind 56% (36) after 2.4 and 3.6 g aspiriin per day, respectively, compared to 61% enzyme inactivation which we observe in platelets after 20 (18) . WNhereas the in vivo differences in aspirin sensitivity of various tisstues are probably duie, in part, to drtig distribution, the in vitro sttudies indicate that addlitionial uinknowni factors coniAspirin Int1hibitiotn of Cyclooxitlgt(ase tribute to the difference. The sensitivity of platelets seems relatively specific for aspirin, because we have also studied an aspirin analog, diflunisal (5-[2,4-difluorophenyl]salicylic acid), and have found that seminal vesicle and platelet enzyme are equally inhibited by this drug (37).
Gryglewski et al. (17) have proposed that prostaglandin I2, which inhibits platelet aggregation and is a vasodilator, functions to prevent thrombosis and platelet plug formation. If this hypothesis is correct, aspirin may have opposing effects, i.e., to prevent thrombosis by interfering with platelet thromboxane A2 production and to stimulate thrombosis by blocking PGI2 production in arteries. They further speculate that arteries in vivo may form PGI2 from endoperoxides secreted by platelets (38) as well as from arachidonic acid via arterial cyclooxygenase (39) . It is presently unknown whether or not cyclooxygenase in human coronary arteries and other pertinent tissues is less sensitive to aspirin than the platelet enzyme. If so, the most effective antithrombotic dose of aspirin would be that which inhibits enzyme in platelets but not in other tissues. If vascular tissue depends on endoperoxides secreted by platelets to produce PGI2, then aspirin may not be useful as an antithrombotic agent.
The hemostatic defect caused by aspirin in normal subjects is a minor one, resulting in mild prolongation of the bleeding time. In fact, a patient with complete cyclooxygenase deficiency and only mild clinical symptoms has been described (40) . These data and the fact that aspirin has only subtle effects on thrombininduced platelet reactions indicate that metabolism of arachidonic acid via cyclooxygenase is not essential to platelet function. Rather, this pathway probably serves to modulate the reactions involved in platelet function, perhaps by altering the threshold stimulus necessary to initiate aggregation or release (41) . By irreversibly blocking this pathway at low doses, aspirin would be a useful antithrombotic agent, assuming that the loss of this modulatory pathway favorably affects pathological thrombosis. Only forthcoming controlled clinical trials can verify this assumption.
The low level of side effects attributable to aspirin among occasional users and the fact that common major toxicities are dose-related (42) suggest that chronic aspirin ingestion in the dosage range of <325 mg per day may be well tolerated. Small doses of aspirin will inhibit platelet prostaglandin production to a high degree. It is even conceivable that doses of 20 mg per day might have antithrombotic action inasmuch as the degree to which cyclooxygenase must be inhibited to alter thrombosis is unknown.
